ArticleThe journal of obstetrics and gynaecology research2026
Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology.
Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDespite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.
methodsWe conducted a retrospective survey through the Committee on Gynecologic Oncology of the Japan Society of Gynecology and Obstetrics across 16 institutions.
resultsHistological subtypes included high-grade serous (HGS; n = 304), clear-cell (CC; n = 83), endometrioid (EM; n = 35), mucinous (n = 12), and low-grade serous (n = 9) carcinomas. At recurrence, the median age was 61 years, 74.0% of patients had a platinum-free interval (PFI) ≥ 6 months, and 78.8% maintained a performance status (PS) of 0. Genetic testing identified 42 BRCA1/2 mutations and 52 cases of homologous recombination deficiency positivity. Recurrence occurred primarily in the peritoneum, lymph nodes, and liver. For PFI ≥ 6 months, paclitaxel/carboplatin ± bevacizumab was the primary treatment; for PFI < 6 months, pegylated liposomal doxorubicin ± bevacizumab predominated. The overall response rate was 69.9% for PFI ≥ 6 months versus 17.7% for PFI < 6 months. Median overall survival was 27.9 months. Multivariate analysis confirmed histological subtype (CC/EM vs. HGS), PS, CA125 (≥ 100 U/mL), and PFI as significant independent prognostic factors, while first-line molecularly targeted therapy use showed no significant impact.
conclusionPFI, histological subtype, PS, and CA125 levels are important prognostic factors for the use of molecular-targeted agents for recurrent epithelial ovarian cancer. Patients with CC and EM subtypes experience worse outcomes than those with HGS, highlighting the need for subtype-specific management in recurrent ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.